A week in the life of Edward Draper, founder of Ortheia
Edward Draper is an alumna of the Innovating for Growth: Scale-ups programme and a founder of Ortheia Ltd, a start-up company in the early stages of development of new medical technologies. He leads on commercialising novel products in collaboration with UK-based Universities and other technology-based SMEs, Small and Medium-sized Enterprises. The current flagship product they are developing is a new biomaterial that, when implanted into the body, does two things: helps bones to heal, and fights infection without the need for antibiotics. This is especially important at a time when there is a world-wide increase in resistance to antibiotics.
Edward leads the small but talented team of three that make up Ortheia, which has only been trading for three years. He has a lot of experience of R&D in the MedTech sector and has worked in Universities such as Imperial College and UCL, as well as leading innovation teams in industry. He has led on the technical aspects of product launches in the UK and across the globe and has his name on many patents. The whole Ortheia team share his passion for the challenges of getting new MedTech innovations into the clinics and onto the markets across the world.
Today the team are all working from their homes in different parts of the country because of the COVID19 Lockdown. We spoke to Edward to find out more about what a typical week looks like for him.
Welcome to my Lockdown Lair. It’s an ex-bedroom that I have converted into an office/workshop (I am an inveterate maker). Most of my work is collaborative and is about making sure all the aspects of the work are progressing, despite the restrictions imposed by COVID19. Today I had three major tasks.
First, I am working with my three fellow directors on our Business Risk Register, which may sound a little boring, but in fact it makes us can go through all aspects of the business in quite a lot of detail. This is so important right now because we know from the statistics that Companies at the stage we are in now are most likely to fail. Going through the Business Risks will not guarantee us success, but it is more likely we can spot things early before they go wrong. The meeting was done by the inevitable video call sharing documents over three hours. It was tiring but productive. We are about a quarter of the way through the Register.
Second was the final tasks needed before filing our next patent. This involves chasing up our collaborators for the necessary paperwork and finalising the Figures we need to add.
Third and final, there was some consultancy work I am doing with an exciting Oxford-based company who want to launch new 3D-printed metal implants and I am helping them get regulatory approval here the UK and in the USA. The current work was deciding how best to explain the quite complicated case to the Regulatory Authorities.
We are leading a large project with University of Cambridge and two other SMEs on a grant funded by Innovate UK. Today was the monthly meeting so it was yet another videoconference. The product we are developing looks a bit like granulated sugar (you can see it in the image above), but it is technically quite advanced. This is our flagship product design to speed up bone healing and damping down infection. Today’s meeting was to go through where we were with the manufacture and the lab testing. This needed some preparation time before the meeting and then quite some time in the meeting picking the best option to go forward. I also did some more work on the patent.
I have been elbow deep in Excel. I had two quite critical tasks that I needed to progress quite urgently. The lab results from Cambridge looked as if we’d had a ‘bad cell’ day and I was looking at how the data compare with previous work. It is quite common that data need to be scrutinised in detail like this. We exchanged a lot of emails and we did come to an agreement as to what to do next (wait for the next lot of data that should arrive in a week or so). Once that was settled, I was back in Excel looking at the biomaterials formulations to make sure we have the specifications right. Last part of the day was spent trying to find slots in peoples’ diaries before the end of the week so I can help resolve any issues before they become problems.
We have several months left in the current Innovate UK grant. This has been fabulous and has allowed us to really test out the early formulations of the biomaterials. However, at the end of the grant we will still have a long way to go before we will be investment ready. This means we must plan the next grant in detail. Today we were mapping the technology development out to clinical launch and beyond. To attract the next round of grant funding we have to package up the next few years work in a way that will be attractive to the viewers. So it was another long video call with the three of us sharing big virtual whiteboards. It was very productive, but we still have much further to go before we have an application that is strong enough. Fortunately for us we have some time. The next suitable grant call from Innovate UK will be announced in a few months.
I also had a call with an Academic in the University of Sheffield about an academic project we are planning together to help us understand the underlying phenomena associated with some work we have done in the past on early joint disease and healing cartilage. It is good to keep it progressing. Today also saw my take 30 minutes off to dash to my GP’s surgery for the first of my COVID19 vaccinations; a miraculous technology that hopefully sees the world getting out of this ongoing craziness.
This was a day in which I was being pulled into different directions. We had a call with our Patent Attorney about the final stages of preparing the new patent; we were very nearly there. I just needed to chase up comments from our Collaborators on the patent wording and sort out some Figures. It is not unreasonable to think that we will file in the next month or so. Then a sharp pivot in attention. The consultancy work I am doing needs for me to define what is known to the Regulators as a ‘predicate device’. It needs a detailed search through the FDA’s database, which are all online, and find a product that is currently being sold that is like my client’s. I have come up with a choice of three, which I will work on next week.
I finished the day preparing for next week’s business planning. We have adopted a graphical approach to the five years, and I need to prepare to facilitate the big meeting next week, Yet another video call with a complex ‘Orbit’ on a virtual whiteboard. This afternoon’s efforts were handwritten notes on an A3 copy. I am looking forward to working through this with the team next week.